Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/220017
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVillanueva, Bernat-
dc.contributor.authorSánchez-Corral Mena, Miguel Ángel-
dc.contributor.authorAlba, Esther-
dc.contributor.authorOrdi, Queralt-
dc.contributor.authorRuiz, Yolanda-
dc.contributor.authorTorres Iglesias, Raquel-
dc.contributor.authorPortillo Medina, Alejandro-
dc.contributor.authorIriarte, Adriana-
dc.contributor.authorMonforte, Cristina-
dc.contributor.authorGamundí, Enric-
dc.contributor.authorPintó Sala, Xavier-
dc.contributor.authorRibas, Jesús-
dc.contributor.authorRiera Mestre, Antoni-
dc.date.accessioned2025-03-25T16:40:03Z-
dc.date.issued2025-02-01-
dc.identifier.issn0953-6205-
dc.identifier.urihttps://hdl.handle.net/2445/220017-
dc.description.abstractObjectives: To describe the incidence of pulmonary arteriovenous malformations (PAVM)-related complications, right-to-left shunt (RLS) progression at transthoracic contrast echocardiography (TTCE) and development of treatable PAVM during long-term follow-up in hereditary hemorrhagic telangiectasia (HHT) patients with RLS grades 0-1 at screening TTCE. Methods: Observational prospective study including adult HHT patients with grades 0-1 RLS at screening TTCE. Those requiring previous embolization of PAVM were excluded. PAVM-related complications and RLS progression during follow-up were recorded. Results: 183 patients were followed-up during 5.6 [IQR: 3.3-8.2] years. Seven (3.8 %) patients developed potentially PAVM-related complications, although all of them were considered unrelated to HHT after multidisciplinary assessment. Among 84 patients with a follow-up TTCE, RLS progressed to grades ≥2 in eight (9.5 %). Among patients with grade 0 RLS at screening, 31.6 % evolved to grade 1 RLS during follow-up and none progressed to grade ≥ 2. Among patients with grade 1 RLS at screening, RLS increased in 17.4 %, by one grade in most cases, and two (2.4 %) patients developed treatable PAVM. Grade 1 RLS and a higher epistaxis severity score were associated with RLS progression. Conclusions: In HHT patients with grades 0-1 RLS at screening, PAVM-related complications are rare. No patient with grade 0 RLS showed an increase in RLS of more than one grade on TTCE. Among patients with grade 1 RLS, rescreening every 5 years should be recommended because treatable PAVM can develop; follow-up with TTCE could be an alternative, as it would allow a better selection of patients for chest CT.-
dc.format.extent20 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.ejim.2024.12.006-
dc.relation.ispartofEuropean Journal Of Internal Medicine, 2025, vol. 132, p. 106-112-
dc.relation.urihttps://doi.org/10.1016/j.ejim.2024.12.006-
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2025-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceArticles publicats en revistes (Ciències Clíniques)-
dc.subject.classificationEcocardiografia-
dc.subject.classificationPersones grans-
dc.subject.classificationMalalties vasculars-
dc.subject.otherEchocardiography-
dc.subject.otherOlder people-
dc.subject.otherVascular diseases-
dc.titleLong-term follow-up of hereditary hemorrhagic telangiectasia patients without significant pulmonary right-to-left shunt at screening-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec753704-
dc.date.updated2025-03-25T16:40:03Z-
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccess-
dc.embargo.lift2025-12-10-
dc.date.embargoEndDateinfo:eu-repo/date/embargoEnd/2025-12-10-
dc.identifier.pmid39668082-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
876731.pdf7.66 MBAdobe PDFView/Open    Request a copy


Embargat   Document embargat fins el 10-12-2025


This item is licensed under a Creative Commons License Creative Commons